Cardiotoxicity

Cardioprotection Effect of Linagliptin

Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction

Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors

The CARDIOPROTECT Trial

The STOP-MED CTRCD Trial

ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-up

Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.

Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

Novel On-body Evaluation of Cardiac Health for Oncology

A Study of Blood Pressure Control During Cancer Treatment

Global Cardio Oncology Registry

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy